The recently published multi-institutional analysis demonstrated that the use of upfront EGFR-TKI with deferral of radiotherapy is associated with inferior OS in patients with EGFR-mutant NSCLC who develop brain metastases [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.